19:14 , May 20, 2019 |  BC Extra  |  Clinical News

May 20 Clinical Quick Takes: Keytruda misses in TNBC; plus Medicines Co., Acadia, Takeda, Ocular

Keytruda fails in previously treated TNBC  Monotherapy with PD-1 inhibitor Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK) missed the primary endpoint of improving overall survival vs. physician’s choice of single agent chemotherapy in the...
22:42 , Apr 1, 2019 |  BC Extra  |  Company News

Management tracks: AACR, Acadia, Aerie

The American Association for Cancer Research inaugurated Elaine Mardis as president for 2019-20. She is the co-executive director of the Institute for Genomics Medicine at Nationwide Children’s Hospital and a professor of pediatrics at Ohio...
01:15 , Jan 12, 2019 |  BioCentury  |  Finance

JPM jump-starts 2019

About three quarters of the more than 200 biopharma companies presenting at the 2019 J.P. Morgan Healthcare Conference saw their stock prices rise last week. Leading the pack was the 53% jump by Insmed Inc....
01:03 , Jan 12, 2019 |  BioCentury  |  Finance

Warning: cash needed

  A near decade-long run of cheap money appears to be coming to a close, and most of the biotech sector isn’t well positioned for the new reality. BioCentury’s analysis shows that two-thirds of biotech...
22:09 , Dec 17, 2018 |  BC Extra  |  Company News

Management tracks: Vertex’s Graney joins Generation Bio

Tom Graney has left Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) as CFO to take on the same role at non-viral gene therapy company Generation Bio Co. (Cambridge, Mass.). Ian Smith, Vertex EVP and COO and former CFO,...
18:28 , Nov 30, 2018 |  BC Week In Review  |  Financial News

Follow-on roundup: Acadia raises $275M, Rocket pockets $55M

CNS company Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) and gene therapy company Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) each priced follow-ons late Nov. 27, raising $275 million and $55 million, respectively. Acadia markets Nuplazid pimavanserin, a small molecule serotonin...
22:43 , Nov 28, 2018 |  BC Extra  |  Financial News

Follow-on roundup: Acadia raises $275M, Rocket pockets $55M

CNS company Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) and gene therapy company Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) each priced follow-ons late Tuesday, raising $275 million and $55 million, respectively. Acadia markets Nuplazid pimavanserin, a small molecule serotonin receptor...
22:55 , Oct 30, 2018 |  BC Extra  |  Company News

Management tracks: Blueprint, Clovis

Ahead of the anticipated 2019 launch of avapritinib, Blueprint Medicines Corp. (NASDAQ:BPMC) hired Christina Rossi into the newly created role of chief commercial officer. She was the multiple sclerosis business unit head of North America...
23:48 , Oct 15, 2018 |  BC Extra  |  Company News

Management tracks: Rhythm, Redpin

Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) hired Murray Stewart as CMO of the metabolic disorder company. Stewart was CMO of GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) until 2017 when he became head of R&D at Novelion Therapeutics Inc. (NASDAQ:NVLN)....
21:55 , Oct 8, 2018 |  BC Extra  |  Company News

Management tracks: As Akcea shifts to commercialization, Crooke resigns from board

Akcea Therapeutics Inc. (NASDAQ:AKCA) said Stanley Crooke, founder, chairman and CEO of parent company Ionis Pharmaceuticals Inc. (NASDAQ:IONS), resigned from Akcea's board. Ionis CBO Damien McDevitt will take Crooke's place on Akcea's board. An Ionis...